Adalimumab Pricing and Market Exclusivity for Biologics

Abstract

To the Editor: In our Perspective article about market exclusivity for biologics (Nov. 12, 2009, issue),1 the table provided the cost to consumers for adalimumab for the treatment of Crohn's disease, for which the approved dose is an induction of 160 mg, followed by 80 mg 2 weeks later, and then 40 mg every other week for a year. The value of $50,933 was derived from a publicly available listing in 2009 on Drugstore.com, a widely used Internet pharmacy site, where the product was described as “1 box = two 20 mg/0.4 mL syringes” and the price per box was . . .